The potential approval of Vertex’s IgAN therapy povetacicept in 2026 comes amid launch headwinds for the company’s non-opioid ...

The stock, which is down more than 61% in 2025, sold off after reporting a Q3 EPS beat missing on revenue expectations.

Q3 2025 Earnings Call Transcript November 3, 2025 Vertex, Inc. reports earnings inline with expectations. Reported EPS is ...

Vertex Pharmaceuticals VRTX reported adjusted earnings of $4.80 per share for the third quarter of 2025, surpassing the Zacks ...

( (VERX) ) has released its Q3 earnings. Here is a breakdown of the information Vertex, Inc. presented to its investors.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off!

CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.

Relyance AI, the leading AI-native data security platform, today announced a limited-time free trial program for its AI ...

These awards reflect the vision of organization founder Dr. Irving Fradkin, whose pioneering work in establishing ...

Get insights from Vertex Pharmaceuticals' Q3 2025 earnings call—revenue growth, pipeline milestones, and outlook for ALYFTREK, CASGEVY, and JOURNAVX.

Election Day, or the general election, is Tuesday, Nov. 4. In the general election, voters will consider statewide ...

Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges ...

The ClearBridge Large Cap Growth ESG Strategy underperformed its Russell 1000 Growth Index benchmark in the third quarter.